Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Featured content in this Issue: This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Source

ChatGPT outperforms trainee doctors in respiratory disease assessments

The chatbot ChatGPT performed better than trainee doctors in assessing complex cases of respiratory disease in areas such as cystic fibrosis, asthma and chest infections

September 9, 2024

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

At the recent American Society of Hematology (ASH) annual meeting, updated data on mosunetuzumab (Lunsumio) in relapsed/refractory follicular lymphoma revealed durable responses, particularly in high-risk

December 20, 2024

Covid-19 may raise risk of developing multiple sclerosis

Covid-19 may be a risk factor for multiple sclerosis (MS). This has been shown by new research at örebro University and örebro University Hospital, Sweden.

November 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.